Explore › Intervention › Vitamin K
Intervention

Vitamin K

Also known as: Product containing vitamin K Product containing vitamin K (medicinal product) Product containing vitamin K (product) Product containing vitamin K and vitamin K derivative (product) Product containing vitamin K and/or vitamin K derivative (product) Vitamin K Vitamin K (substance) Vitamin K and vitamin K derivative Vitamin K and vitamin K derivative (substance) Vitamin K and/or vitamin K derivative Vitamin K and/or vitamin K derivative (substance) Vitamin K and/or vitamin K derivative-containing product +8 more
3 findings 1 paper 4 related entities View in graph →

Related entities

conditions
Fontan Circulation1
outcomes
Bleeding events1
populations
Pregnant Women1
studys
PMC103671271

Findings (27)

None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →
None
adverse

Vitamin K antagonist use during pregnancy in women with Fontan physiology was significantly associated with bleeding events compared to no antithrombotic therapy (OR 11.7, 95% CI 1.06-130, p=0.032).

Effect: adverse; OR 11.7; CI: 95% CI 1.06 to 130

Size: OR 11.7 CI: 95% CI 1.06 to 130
PMC10367127
Finding details → · Paper → · Graph →

Papers (1)